September 20th 2021, 9:00pm
A study from the International Parkinson and Movement Disorder Society Virtual Congress suggest that despite protocol adherence, average costs are moderately high and vary significantly.
September 20th 2021, 5:00pm
The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel discussed future use of medical cannabis and concerns for psychiatric adverse effects.
September 20th 2021, 1:00pm
The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel outlined the small, retrospective study, shedding light on its findings.
September 19th 2021, 7:00pm
The FIGHT-PD study is expected to complete and read out interim results before the end of 2021. It aims to assess the exercise program’s safety, tolerability, and efficacy in Parkinson disease.
September 19th 2021, 4:00pm
The professor of neurology at Weill Cornell Medical School commented on the available treatments for Parkinson disease, as well as ongoing therapeutic development.
September 18th 2021, 7:00pm
Patients who underwent deep brain stimulation procedures that were managed postoperatively in the home reported significantly fewer clinic visits with similar MDS-UPDRS scores to standard of care.
September 18th 2021, 4:00pm
Investigators noted the psychiatric adverse effects of treatment with medical cannabis, requiring patient monitoring after initiation.
September 18th 2021, 2:00pm
Despite not meeting the primary end point, those in the early-start group showed reduced change from baseline in MDS-UPDRS-III scores compared with the delayed-start group at both weeks 52 and 104.
September 17th 2021, 9:00pm
Data from the PRIME-NL study showed stressors resulting from the pandemic impacted depression, anxiety, and quality of life.
September 17th 2021, 3:00pm
Improvements in mean total amount of time and percentage of participants that were awake suggested limited effect with opicapone (Ogentys; Neurocrine Bio).